
FDA Grants Breakthrough Therapy to IDE196 in Primary Uveal Melanoma
Treatment with IDE196 (darovasertib) has been granted Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the neoadjuvant treatment of adult patients with primary uveal melanoma for whom enucleation has been …